Showing 621-630 of 4005 results for "".
Radium-223’s Potential Quality of Life Benefits for mCRPC Patients
https://reachmd.com/programs/project-oncology/radium-223s-potential-quality-of-life-benefits-for-mcrpc-patients/28642/Dive into a study that explored how radium-223 may be able to boost the quality of life of patients battling metastatic castration-resistant prostate cancer.The Digital Dermatologist: Why Physicians Should Embrace Coding Skills in the Modern Era
https://reachmd.com/programs/practical-dermatology/the-digital-dermatologist-why-physicians-should-embrace-coding-skills-in-the-modern-era/24034/A changing digital landscape means practitioners need to keep their digital toolkits up to date.Forging a Path Toward Cardiac Applications for Stem Cells
https://reachmd.com/programs/heart-matters/forging-a-path-toward-cardiac-applications-for-stem-cells/4549/Cardiac disease was once thought to be both progressive and irreversible. As stem cell therapies emerge across many fields of medicine, our patients with cardiac disorders may be among the first to benefit from this translation of basic science into very valuable clinical applications. What do the lArtificial Intelligence in Clinical Neurology: Opportunities, Limitations, and the Path Forward
https://reachmd.com/diseases-diagnoses/imaging-testing/artificial-intelligence-in-clinical-neurology-opportunities-limitations-and-the-path-forward/56386/Artificial intelligence is revolutionizing clinical neuroimaging by enhancing how neurologic conditions are diagnosed, prioritized, and managed, but its challenges must be addressed to ensure safe and fair use across diverse patient populations.Keeping CALM in Crohn’s Disease: An Exploration of Biomarker Cutoffs & Endoscopic Outcomes
https://reachmd.com/programs/crohns-colitis-foundation-perspectives/keeping-calm-in-crohns-disease-an-exploration-of-biomarker-cutoffs-and-endoscopic-outcomes/12434/What does the CALM study tell us about biomarker cutoffs and endoscopic outcomes in Crohn’s disease?How Epidermolysis Bullosa Treatments Went from Blisters to Breakthroughs
https://reachmd.com/topics/rare-disease/how-epidermolysis-bullosa-treatments-went-from-blisters-to-breakthroughs/54391/Current FDA-approved therapies oleogel-S10, beremagene geperpavec, and prademagene zamikeracel represent major therapeutic breakthroughs for the treatment of epidermolysis bullosa (EB). Earlier systemic intervention, improved nutrition, and proactive management of complications have extended survivThe 25th Anniversary of the Discovery of the Hepatitis C Virus: Looking Back to Look Forward
https://reachmd.com/programs/grand-rounds-nation/CDC-Hepatitis/7028/Twenty-five years ago CDC played a pivotal role in the discovery of the virus that causes hepatitis C. After the isolation of HCV, implementation of screening of blood products and organs for donation led to a decrease in rates of HCV infection between 1990 and 2009. In spite of these successes, HCVConfronting Antisemitism in Medicine and Dermatology
https://reachmd.com/ma-issues-index/march-april-2026-issue/confronting-antisemitism-in-medicine-and-dermatology/56632/Why rising hate demands action from physicians and practice leadersExploring the Emergency Use Authorization for a Monoclonal Antibody Cocktail for COVID-19
https://reachmd.com/programs/the-drug-report/exploring-the-emergency-use-authorization-for-a-monoclonal-antibody-cocktail-for-covid-19/12025/Here’s what led the FDA to issue an EUA for the coadministration of casirivimab and imdevimab to block COVID-19’s attachment and entry into cells.Ramping Up to Manage COVID-19 Patients
https://reachmd.com/programs/covid-19-frontlines/ramping-up-to-manage-covid-19-patients/11527/Every COVID-19 care team has unique issues based on their situation, which is why collaboration and communication is key.